These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33137294)

  • 1. Setmelanotide: what does it mean for clinical care of patients with obesity?
    Ryan DH
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):933-935. PubMed ID: 33137294
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
    Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist.
    Bischof JM; Van Der Ploeg LH; Colmers WF; Wevrick R
    Br J Pharmacol; 2016 Sep; 173(17):2614-21. PubMed ID: 27339818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.
    Kühnen P; Clément K; Wiegand S; Blankenstein O; Gottesdiener K; Martini LL; Mai K; Blume-Peytavi U; Grüters A; Krude H
    N Engl J Med; 2016 Jul; 375(3):240-6. PubMed ID: 27468060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone-Replacement Therapy for Melanocyte-Stimulating Hormone Deficiency.
    Reitman ML
    N Engl J Med; 2016 Jul; 375(3):278-9. PubMed ID: 27468065
    [No Abstract]   [Full Text] [Related]  

  • 6. Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies.
    Wabitsch M; Fehnel S; Mallya UG; Sluga-O'Callaghan M; Richardson D; Price M; Kühnen P
    Adv Ther; 2022 Apr; 39(4):1772-1783. PubMed ID: 35192151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.
    Kühnen P; Wabitsch M; von Schnurbein J; Chirila C; Mallya UG; Callahan P; Gnanasakthy A; Poitou C; Krabusch PM; Stewart M; Clément K
    Orphanet J Rare Dis; 2022 Feb; 17(1):38. PubMed ID: 35123544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Setmelanotide (Imcivree) for rare genetic forms of obesity.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e3-e4. PubMed ID: 34544109
    [No Abstract]   [Full Text] [Related]  

  • 9. Setmelanotide: First Approval.
    Markham A
    Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro-opiomelanocortin (POMC) deficiency and peripheral melanocortins in obesity.
    Zemel MB; Shi H
    Nutr Rev; 2000 Jun; 58(6):177-80. PubMed ID: 10885325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asp10 in Lys-gamma2-MSH determines selective activation of the melanocortin MC3 receptor.
    Oosterom J; Burbach JP; Gispen WH; Adan RA
    Eur J Pharmacol; 1998 Jul; 354(1):R9-11. PubMed ID: 9726642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Precision Medicines: Curing POMC Deficiency.
    Müller TD; Tschöp MH; O'Rahilly S
    Cell Metab; 2016 Aug; 24(2):194-5. PubMed ID: 27452145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term MC4R Agonist Treatment in POMC-Deficient Patients.
    Kühnen P; Clément K
    N Engl J Med; 2022 Sep; 387(9):852-854. PubMed ID: 36053514
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.
    Haws R; Brady S; Davis E; Fletty K; Yuan G; Gordon G; Stewart M; Yanovski J
    Diabetes Obes Metab; 2020 Nov; 22(11):2133-2140. PubMed ID: 32627316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agouti-related protein (83-132) is a competitive antagonist at the human melanocortin-4 receptor: no evidence for differential interactions with pro-opiomelanocortin-derived ligands.
    Pritchard LE; Armstrong D; Davies N; Oliver RL; Schmitz CA; Brennand JC; Wilkinson GF; White A
    J Endocrinol; 2004 Jan; 180(1):183-91. PubMed ID: 14709157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesity.
    Pritchard LE; Turnbull AV; White A
    J Endocrinol; 2002 Mar; 172(3):411-21. PubMed ID: 11874690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.
    Falls BA; Zhang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R.
    Haskell-Luevano C; Hendrata S; North C; Sawyer TK; Hadley ME; Hruby VJ; Dickinson C; Gantz I
    J Med Chem; 1997 Jul; 40(14):2133-9. PubMed ID: 9216831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leptin infusion and obesity in mouse cause alterations in the hypothalamic melanocortin system.
    Gout J; Sarafian D; Tirard J; Blondet A; Vigier M; Rajas F; Mithieux G; Begeot M; Naville D
    Obesity (Silver Spring); 2008 Aug; 16(8):1763-9. PubMed ID: 18551122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the melanocortin 3 receptor in mediating the effects of gamma-MSH peptides on the adrenal.
    Harmer SC; Bicknell AB
    Endocr Res; 2004 Nov; 30(4):629-35. PubMed ID: 15666803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.